TNF Inhibitors in Takayasu's Arteritis Save
A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis.
This multicentre study enrolled patients from Takayasu's referral centers in France, Italy, Spain, Armenia, Israel, Japan, Tunisia, and Russia, between January 2017 to September 2019.
From a total of 135 TAK patients, 34 received adalimumab (ADA) and 101 infliximab (INFLX) for at least 3 months. After 6 months of therapy, 71% achieved complete response (NIH < 2 with <7.5 mg/day prednisone)
- 68% on adalimumab
- 73% on infliximab (NS).
A complete response was associated with age < 30 years, tobacco use, vascular signs at initiation, NIH ≥ 2, CRP> 20 mg/l, and a starting dose >20 mg/day of prednisone.
The risk of relapse at 12 months was at 10.9% on ADA and 16.8% on INFLX, after a median of 23 months followup.
Both infliximab and adalimumab are effective in TAK, without significant differences in the risk of relapse and revascularization.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.